- Home
- CBOE vs RPRX Comparison
CBOE vs RPRX Comparison
Compare CBOE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | RPRX |
|---|---|---|
| Founded | 1973 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 22.0B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBOE | RPRX |
|---|---|---|
| Price | $248.99 | $57.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $289.44 | $51.40 |
| AVG Volume (30 Days) | 1.8M | ★ 3.5M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | 0.94% | ★ 1.90% |
| EPS Growth | ★ 44.52 | N/A |
| EPS | ★ 3.66 | 0.67 |
| Revenue | $2,229,100,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | $3.54 | $4.73 |
| P/E Ratio | ★ $68.01 | $86.22 |
| Revenue Growth | ★ 239.31 | 5.06 |
| 52 Week Low | $227.15 | $34.63 |
| 52 Week High | $371.18 | $57.79 |
Technical Indicators
Market Signals| Indicator | CBOE | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 63.95 |
| Support Level | $241.99 | $38.07 |
| Resistance Level | $255.72 | N/A |
| Average True Range (ATR) | 12.92 | 1.50 |
| MACD | -0.32 | 0.16 |
| Stochastic Oscillator | 29.84 | 99.55 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.